Estrogens, acting through the estrogen receptors, ER? and ER?, control many physiological and pathological processes in numerous target tissues. While progress has been made in developing ER ligands having more desirable patterns of selective activity, such as selective ER modulators (SERMs) and ER-subtype selective ligands, the diversity of modes and pathways through which the ERs act offers intriguing but as yet unexplored mechanisms through which one should be able to obtain new compounds having higher levels of desired selectivity. Our overall goal is to develop potent ER ligands optimized to deliver the full range of desired, long sought-after selectivity in three medically important areas, achieved by three distinct mechanisms: (A) brain neuroprotection mediated through ER? with carefully selected ligands of novel structure;(B) cardiovascular protection afforded by selective activation of extranuclear-initiated ER signaling pathways by estrogen-dendrimer conjugates (EDCs) and small molecules of novel design;and (C) combined anti-proliferative/anti-inflammatory activity as optimized therapy for estrogen-dependent breast cancer and endometriosis, through unique ER conformations induced by structurally novel ligands. Each effort is centered on a distinct mechanistic paradigm and is supported by active, ongoing collaborations with established research groups that should lead to excellent opportunities for further pre-clinical development.
Aims : (1) Develop Novel ER? Ligands Having Selective Brain Neuroprotective Activities. A subset of our ER? ligands, acting through an endogenous autocrine anti-inflammatory pathway, is neuroprotective and is active in animal models of multiple sclerosis, reversing established disease. We will develop structure-activity relationships to enhance potency and selectivity of these novel compounds. (2) Develop Novel Pathway-Specific ER Ligands that Afford Selective Vascular, Cardiac, and Bone Protection. Our EDC blocks hormone entry into the nucleus and activates only the extranuclear-initiated ER signaling pathway, yet it provides cardiovascular protection equivalent to that of estradiol without stimulation of uterus or breast tumors. We will develop orally active conjugates with highly stable dendrimers and carefully designed small molecules having pathway selectivity. (3) Develop Novel ER Ligands that Combine Anti- Inflammatory and Anti-Proliferative Activities for Improved Therapy for Endocrine-Resistant Breast Cancers and Endometriosis. Our 3-dimensional ER ligands stabilize a previously unseen ER conformation and inhibit hormone-resistant breast cancer lines and endometriotic lesions. Using structure-guided design, we will develop higher potency and more selective compounds.
There have been tremendous advances in our understanding of how estrogens regulate diverse physiological and pathological processes, through the two estrogen receptors, ER? and ER?, using multiple pathways, and relying on different receptor conformations and interaction partners. At this particularly opportune time, we will explore novel mechanisms to obtain important forms of selective estrogen action by developing new ER ligands that will provide neuroprotection of the brain and protect the cardiovascular system without putting the uterus and breast at risk, and afford improved therapy for breast cancer and the management of endometriosis. New compounds working by these novel mechanisms should be excellent starting points for the clinical development of important, new therapeutic agents.
|Paterni, Ilaria; Granchi, Carlotta; Katzenellenbogen, John A et al. (2014) Estrogen receptors alpha (ER?) and beta (ER?): subtype-selective ligands and clinical potential. Steroids 90:13-29|
|Dabrota, Cristian; Asim, Muhammad; Choueiri, Christine et al. (2014) Synthesis and receptor binding in trans-CD ring-fused A-CD estrogens: comparison with the cis-fused isomers. Bioorg Med Chem Lett 24:3841-4|
|Aguilar, Helena; Urruticoechea, Ander; Halonen, Pasi et al. (2014) VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Res 16:R53|
|Adlanmerini, Marine; Solinhac, Romain; Abot, Anne et al. (2014) Mutation of the palmitoylation site of estrogen receptor * in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci U S A 111:E283-90|
|Abot, Anne; Fontaine, Coralie; Buscato, Mélissa et al. (2014) The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor ? modulation, uncoupling nuclear and membrane activation. EMBO Mol Med 6:1328-46|
|Royston, S E; Yasui, N; Kondilis, A G et al. (2014) ESR1 and ESR2 differentially regulate daily and circadian activity rhythms in female mice. Endocrinology 155:2613-23|
|Li, Zhiping; Chen, Ke; Jiao, Xuanmao et al. (2014) Cyclin D1 integrates estrogen-mediated DNA damage repair signaling. Cancer Res 74:3959-70|
|Asim, Muhammad; Klonowska, Daria; Choueiri, Christine et al. (2012) BC-spiro-estradiols. Synthesis and estrogen receptor binding affinity of four new estradiol isomers. Bioorg Med Chem Lett 22:3713-7|
|Kieser, Karen J; Kim, Dong Wook; Carlson, Kathryn E et al. (2010) Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs). J Med Chem 53:3320-9|
|Chambliss, Ken L; Wu, Qian; Oltmann, Sarah et al. (2010) Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest 120:2319-30|
Showing the most recent 10 out of 40 publications